|
|
| | 8-Chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]amino]-3-Quinolinecarbonitrile Basic information |
| Product Name: | 8-Chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]amino]-3-Quinolinecarbonitrile | | Synonyms: | 8-Chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]amino]-3-Quinolinecarbonitrile;6-[[[1-[2-(Azepan-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]amino]-8-chloro-4-[(3-chloro-4-fluorophenyl)amino]quinoline-3-carbonitrile;Cot inhibitor-1;3-Quinolinecarbonitrile, 8-chloro-4-[(3-chloro-4-fluorophenyl)aMino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]Methyl]aMino]-;3-triazol-4-yl]methyl]amino]-;8-chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1;Cot inhibitor 1,Cot inhibitor1 | | CAS: | 915365-57-0 | | MF: | C27H27Cl2FN8 | | MW: | 553.46 | | EINECS: | | | Product Categories: | | | Mol File: | 915365-57-0.mol | ![8-Chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]amino]-3-Quinolinecarbonitrile Structure](CAS/GIF/915365-57-0.gif) |
| | 8-Chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]amino]-3-Quinolinecarbonitrile Chemical Properties |
| Boiling point | 730.0±70.0 °C(Predicted) | | density | 1.42 | | storage temp. | Store at -20°C | | solubility | DMSO : 25 mg/mL (45.17 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | | form | Powder | | pka | 8.80±0.20(Predicted) | | color | Light yellow to yellow |
| | 8-Chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]amino]-3-Quinolinecarbonitrile Usage And Synthesis |
| Uses | Cot inhibitor-1 (compound 28) is a selective tumor progression loci-2 (Tpl2) kinase inhibitor with an IC50 of 28 nM. Cot inhibitor-1 shows an inhibition of TNF-alpha production in human whole blood with an IC50 of 5.7 nM[1]. | | References | [1] Junjun Wu, et al. Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3485-8. DOI:10.1016/j.bmcl.2009.05.009 |
| | 8-Chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]amino]-3-Quinolinecarbonitrile Preparation Products And Raw materials |
|